Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Swedish Orphan Biovitrum AB ( (SE:SOBI) ) just unveiled an announcement.
Swedish Orphan Biovitrum AB (Sobi) announced an increase in its total number of shares and votes as of August 29, 2025, due to the issuance of 1,412,788 class C shares. These shares are intended to fulfill commitments under the company’s long-term incentive programs, reflecting Sobi’s strategic efforts to enhance its operational structure and stakeholder engagement.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK314.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Sobi is a global biopharma company focused on breakthrough innovations for rare diseases, with around 1,900 employees across various regions including Europe, North America, the Middle East, Asia, and Australia. In 2024, the company reported a revenue of SEK 26 billion and is listed on Nasdaq Stockholm.
Average Trading Volume: 291,969
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK100B
For an in-depth examination of SOBI stock, go to TipRanks’ Overview page.